QIAGEN Fully Acquires NeuMoDx Molecular Rounding Out Portfolio of PCR-Based Diagnostic Automation Systems
September 17, 2020 QIAGEN N.V. today announced the acquisition of the remaining 80.1% of diagnostics instruments company NeuMoDx Molecular, Inc. for $248 million in cash. The move rounds out QIAGEN’s portfolio of automated molecular testing solutions based on the proven PCR technology. The transaction was completed after QIAGEN received U.S. regulatory clearance for the full […]
